Antibody Research Technology Center

抗体研究技术中心

• 批准号: 8666864
• 负责人: James D. Marks
• 金额: $ 154.95万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-24 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8666864
• 关键词: Antibodies; Antigens; Automobile Driving; Bacteriophages; Biological Assay; Biomedical Research; California; Cell Line; Educational workshop; Extracellular Protein; Funding; Generations; Genes; Goals; Health; Libraries; Membrane Proteins; Methods; Peptide Hydrolases; Plasmids; Post-Translational Protein Processing; Proteins; Proteome; Publications; Reagent; Recombinant Antibody; Research; Research Personnel; Resources; San Francisco; Technology; Training; United States National Institutes of Health; Universities; Visit; Yeasts; conformer; extracellular; novel; protein function; research and development; symposium; technology development; vector

DESCRIPTION (provided by applicant): The goal of the Antibody Technology Resource Center (ATRC) is to develop technologies to generate high quality recombinant antibodies (rAbs) to high-value protein targets that have proven difficult for Ab generation. Abs are essential reagents for determining how proteins function under normal and pathophysiological conditions yet are not available for much of the proteome and when available are of -variable quality. The generation of widely available, renewable, validated and standardized sets of rAbs will significantly accelerate studies of protein function. We are focusing on generating rAbs to secreted extracellular and membrane proteins and protein post-translational modifications since: 1) they comprise 20-40% of all proteins and 2) they have proven challenging to either express, purify and/or successfully use for Ab generation. The ATRC at the University of California, San Francisco (UCSF) has three Technology Research and Development (TR&D) projects that will develop novel high throughput antigen and antibody generation technology to generate rAbs. Project 1) Develop technology to generate rAbs to secreted extracellular, single pass and multipass membrane proteins using yeast displayed antigens, cell lines and phage antibody libraries, Project Leader: James D. Marks; Project 2) Develop technology to generate functional rAbs to proteases that modulate protease function, Project Leader: Charles Craik; and Project 3) Develop technology to generate rAbs to post-translational modifications and their conformers, Project Leader: James Wells. Driving biomedical projects at UCSF and elsewhere will inform target selection, provide some of the antigens and use and validate rAbs generated by the Center for structural and functional assays. These ongoing NIH-funded projects will benefit from ready access to high quality rAbs. Training in the technologies will be accomplished by hosting an annual symposium, workshops, webinars, and by onsite training of visiting investigators in the use of technology. Dissemination of reagents will be accomplished by publication of methods, and by distribution of plasmids containing antibody genes, antibody vectors, antibody expressing cell lines and antibody reagents.

描述（由申请人提供）：抗体技术资源中心（ATRC）的目标是开发技术，以针对已证明难以产生抗体的高价值蛋白质靶标产生高质量重组抗体（rAb）。抗体是确定蛋白质在正常和病理生理条件下如何发挥功能的必要试剂，但对于大多数蛋白质组是不可用的，并且当可用时具有可变的质量。广泛可用的、可再生的、经过验证的和标准化的rAb集的产生将显著加速蛋白质功能的研究。我们专注于产生分泌的细胞外和膜蛋白和蛋白质翻译后修饰的rAb，因为：1）它们占所有蛋白质的20-40%，2）它们已被证明具有表达，纯化和/或成功用于Ab产生的挑战。加州大学旧金山分校弗朗西斯科（UCSF）的ATRC有三个技术研究和开发（TR&D）项目，将开发新的高通量抗原和抗体生成技术，以生成rAb。项目1：利用酵母展示抗原、细胞系和噬菌体抗体库，开发针对分泌的细胞外、单次和多次膜蛋白的rAb技术，项目负责人：James D.商标;项目2）开发技术以产生调节蛋白酶功能的蛋白酶的功能性rAb，项目负责人：Charles Craik;和项目3）开发技术以产生翻译后修饰及其构象异构体的rAb，项目负责人：James威尔斯。在加州大学旧金山分校和其他地方推动生物医学项目将为目标选择提供信息，提供一些抗原，并使用和验证该中心产生的rAb进行结构和功能测定。这些正在进行的NIH资助的项目将受益于随时获得高质量的rAbs。技术培训将通过举办年度专题讨论会、讲习班、网络研讨会以及对访问调查员进行技术使用方面的现场培训来完成。通过公布方法和分发含有抗体基因的质粒、抗体载体、抗体表达细胞系和抗体试剂来完成试剂的传播。